Early Data On JAK Inhibitor Show Incyte And Lilly Are In The Race In Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
It's early days in the oral RA race, but data so far suggest the Incyte/Lilly compound could hold its own against Pfizer's front-runner tasocitinib.